XNAS
CTXR
Market cap13mUSD
Oct 08, Last price
0.49USD
1D
-2.47%
1Q
-16.13%
IPO
-99.36%
Name
Citius Pharmaceuticals Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
33.48%
Rev. gr., 5y
%
Revenues
0
Net income
-37m
L-4.36%
CFO
-27m
L-5.85%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Key people
Jaime Bartushak
Chief Financial Officer, Chief Business Officer · since 2022
Myron Czuczman
Chief Medical Officer, Executive Vice President · since 2020
Executive Vice Chairman of the Board · since 2022
Leonard Mazur
Executive Chairman of the Board, Chief Executive Officer, Company Secretary · since 2022
Suren Dutia
Independent Director · since 2015
Eugene Holuka
Independent Director · since 2016
Dennis McGrath
Independent Director · since 2023
Robert Smith
Independent Director · since 2024
Carol Webb
Independent Director · since 2016
Legal address
C/O CSC Services of Nevada, Inc.
2215-B Renaissance Drive
Las Vegas, NV 89119
US
2215-B Renaissance Drive
Las Vegas, NV 89119
US
Headquarters
1st Floor
11 Commerce Drive
Cranford, NJ 07016
US
11 Commerce Drive
Cranford, NJ 07016
US
Previous name
TrailOne, Inc.
Previous name
Trail One, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||